Xilio's XTX601 Shows Promising Preclinical Data in CLDN18.2 Targeting
Event summary
- XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models.
- XTX601 was well tolerated in non-human primates with a favorable therapeutic index.
- Xilio plans to advance XTX601 into IND-enabling studies and submit an IND application in 2027.
- Preclinical data presented at the AACR Annual Meeting on April 20, 2026.
The big picture
Xilio Therapeutics' presentation of preclinical data for XTX601 at the AACR Annual Meeting highlights the potential of its masked T cell engager technology to address systemic toxicities associated with current treatments. The data supports Xilio's strategy of developing immuno-oncology therapies that selectively activate within the tumor microenvironment, positioning the company as a key player in the evolving landscape of cancer therapeutics. The planned IND application in 2027 marks a critical milestone in Xilio's development pipeline.
What we're watching
- Clinical Translation
- Whether XTX601's promising preclinical profile will translate into clinical success.
- IND Timeline
- The pace at which Xilio can advance XTX601 through IND-enabling studies and achieve regulatory approval.
- Competitive Positioning
- How Xilio's masked T cell engager technology differentiates it from competitors in the CLDN18.2 targeting space.
Related topics